🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Omer Karrar

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0001-6026-4073
Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial”.

Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial

The Lancet Haematology(2024)10.1016/s2352-3026(24)00250-3
N/A
0.561DataRank · unranked
17 citations

Daniel Nguyen, Elias Jabbour, Jayastu Senapati, Zhihong Zeng, Ghayas C. Issa +14 more

Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab

Journal of Hematology & Oncology(2025)10.1186/s13045-025-01709-y
N/A
0.471DataRank · unranked
17 citations

Hagop Kantarjian, Ken Furudate, Nitin Jain, Farhad Ravandi, Omer Karrar +8 more

Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia

Blood Advances(2025)10.1182/bloodadvances.2025016565
N/A
0DataRank · unranked
3 citations

Hagop M. Kantarjian, Nitin B. Jain, Tapan M. Kadia, Jayastu Senapati, Fadi Haddad +12 more

Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor

Haematologica(2025)10.3324/haematol.2025.288553
N/A
0DataRank · unranked
2 citations

Sanam Loghavi, Musa Yılmaz, Omer Karrar, Kunhwa Kim, Courtney D. DiNardo +15 more